Bibliography
- ZLOTNIK A, YOSHIE 0: Chemokines: a new classification system and their role in immunity. Immunity (2000) 12(2):121–127.
- ROTA, VON ANDRIAN UH: Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Ann. Rev Immune]. (2004) 22:891–928.
- GERARD C, ROLLINS BJ: Chemokines and disease. Nat. hmnunol. (2001) 2(2):108–115.
- CASCIERI MA, SPRINGER MS: The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention. Curl: Opin. Chem. Biol. (2000) 4(4):420–427.
- ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci. (2002) 23(10):459–467.
- NEOTE K, DIGREGORIO D, MAK JY, HORUK R, SCHALL TJ: Molecular cloning, functional expression, and signalling characteristics of a C-C chemokine receptor. Cell (1993) 72(3):415–425.
- GAO J-L, KUHNS DB, TIFFANY HL et al: Structure and functional expression of the human macrophage inflammatory protein la/RANTES receptor. I Exp. Med. (1993) 177 (5): 1421–1427.
- MONTECLARO FS, CHARO IF: The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/ MIP-la receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. (1996) 271(32):19084–19092.
- PEASE JE, WANG J, PONATH PD, MURPHY PM: The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP- la and eotaxin binding, respectively, but a second domain is essential for receptor activation. J. Biol. Chem. (1998) 273:19972–19976.
- WONG M, FISH EN: RANTES and MIP-la activate stats in T cells. J. Biol. Chem. (1998) 273(1):309–314.
- GONG X, GONG W, KUHNS DB et al:Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J. Biol. Chem. (1997) 272:11682–11685.
- YOUN BS, ZHANG SM, LEE EK et al:Molecular cloning of leukotactin-1: a novel human 13-chemokine, a chemoattractant for neutrophils, monocytes, and lymphocytes, and a potent agonist at CC chemokine receptors 1 and 3. J. Immunol (1997) 159:5201–5205.
- SARAU HM, RUSH JA, FOLEY JJ et al: Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function. J. Pharmacol Exp. Ther. (1997) 283(1):411–418.
- WEBER C, WEBER KS, KLIER C et al: Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T (H)l-like/CD45R0(+) T cells. Blood (2001) 97(4):1144–1146.
- EIS V, LUCKOW B, VIELHAUER V et al: Chemokine receptor CCR1 but not CCR5 mediates leukocyte recruitment and subsequent renal fibrosis after unilateral ureteral obstruction. I Am. Soc. Nephrol (2004) 15(2):337–347.
- •This paper highlights a non-redundant role for CCR1 in inflammation.
- BROXMEYER HE, COOPERS, HANGOC G, GAO JL, MURPHY PM: Dominant myelopoietic effector functions mediated by chemokine receptor CCR1. J. Exp. Med. (1999) 189(12):1987–1992.
- •This paper highlights a non-redundant role for CCR1 in inflammation.
- GAO JL, WYNN TA, CHANG Y et al: Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. (1997) 185(11):1959–1968.
- •This paper highlights a non-redundant role for CCR1 in inflammation.
- GERARD C, FROSSARD JL, BHATIA M et al.: Targeted disruption of the 13-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. Clin. Invest. (1997) 100(8):2022–2027.
- •This paper highlights a non-redundant role for CCR1 in inflammation.
- KASAMA T, STRIETER RM, STANDIFORD TJ, BURDICK MD, KUNKEL SL: Expression and regulation of human neutrophil-derived macrophage inflammatory protein la. I Exp. Med. (1993) 178:63–72.
- THORNTON S, DUWEL LE, BOIVIN GP, MAY, HIRSCH R: Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression. Arthritis Rheum. (1999) 42(6):1109–1118.
- SZEKANECZ Z, HALLORAN MM, VOLIN MV et al: Temporal expression of inflammatory cytokines and chemokines in rat adjuvant-induced arthritis. Arthritis Rheum. (2000) 43(6):1266–1277.
- KOCH AE, KUNKEL SL, HARLOW LA et al.: Macrophage inflammatory protein-la. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. Clin. Invest. (1994) 93(3):921–928.
- HATANO Y, KASAMA T, IWABUCHI H et al: Macrophage inflammatory protein 1a expression by synovial fluid neutrophils in rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(5):297–302.
- SUZUKI N, NAKAJIMA A, YOSHINO S et al.: Selective accumulation of CCR5' T lymphocytes into inflamed joints of rheumatoid arthritis. Int. Immunol (1999) 11(4):553–559.
- MACCHIONI P, BOIARDI L, MELICONI R et al.: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. Rheumatol (1998) 25(2):320–325.
- LISIGNOLI G, TONEGUZZI S, POZZI C et al: Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin. Exp. Immunol (1999) 116(2):371–378.
- BARNES DA, TSE J, KAUFHOLD M et al.: Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. Clin. Invest. (1998) 101(12):2910–2919.
- BALASHOV KE, ROTTMAN JB, WEINER HL, HANCOCK WW: CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP- la and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA (1999) 96(12):6873–6878.
- McMANUS C, BERMAN JW, BRETT FM et al: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. I. Neuroimmunol (1998) 86(1):20–29.
- TREBST C, SORENSEN TL, KIVISAKK P et al.: CCR1*/CCR5* mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. I Pathol (2001) 159(5):1701–1710.
- TREBST C, STAUGAITIS SM, TUCKY B et al: Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). Neuropathol Appl. Neurobiol (2003) 29(6):584–595.
- KIVISAKK P, TREBST C, LIU Z et al: T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking. Clin. Exp. Immunol (2002) 129(3):510–518.
- RAJAN AJ, ASENSIO VC, CAMPBELL IL, BROSNAN CF: Experimental autoimmune encephalomyelitis on the SJL mouse: effect of y-8 T cell depletion on chemokine and chemokine receptor expression in the central nervous system. Immunol (2000) 164(4):2120–2130.
- FISCHER FR, SANTAMBROGIO L, LUO Y et al.: Modulation of experimental autoimmune encephalomyelitis: effect of altered peptide ligand on chemokine and chemokine receptor expression. Neuroimmunol (2000) 110(1-2):195–208.
- ROTTMAN JB, SLAVIN AJ, SILVA R et al.: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur Immunol (2000) 30(8):2372–2377.
- ADAMS DH, HUBSCHER S, FEAR J et al.: Hepatic expression of macrophage inflammatory protein-la and macrophage inflammatory protein-13 after liver transplantation. Transplantation (1996) 61(5):817–825.
- FAIRCHILD RL, VANBUSKIRK AM, KONDO T, WAKELY ME, OROSZ CG: Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation (1997) 63(12):1807–1812.
- FARVER CE RAYCHAUDHURI B, MALUR A et al.: Increased alveolar macrophage nuclear factor-KB activation and macrophage inhibitory protein-1a levels in lung transplant patients. Transplantation (2000) 70(11):1599–1603.
- PATTISON J, NELSON PJ, HUIE P et al: RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet (1994) 343(8891):209–211.
- PATTISON JM, NELSON PJ, HUIE P, SIBLEY RK, KRENSKY AM: RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant. (1996) 15(12):1194–1199.
- AZZAWI M, HASLETON PS, GERAGHTY PJ et al.: RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45R0 T-lymphocytes and macrophages. J. Heart Lung Transplant. (1998) 17(9):881–887.
- BELPERIO JA, BURDICK MD, KEANE MP et al: The role of the CC chemokine, RANTES, in acute lung allograft rejection. J. Immunol (2000) 165(1):461–472.
- GAO W, TOPHAM PS, KING JA et al: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. Clin. Invest. (2000) 105(1):35–44.
- •Proof-of-principle study showing that the targeting of CCR1 is of beneficial effect in the treatment of allograft rejection.
- TERAN LM, NOSO N, CARROLL M et al.: Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. Immunol (1996) 157:1806–1812.
- POWELL N, HUMBERT M, DURHAM SR et al: Increased expression of mRNA encoding RANTES and MCP-3 in the bronchial mucosa in atopic asthma. Eur. Respir J. (1996) 9(12):2454–2460.
- BERKMAN N, KRISHNAN VL, GILBEY T et al.: Expression of RANTES mRNA and protein in airways of patients with mild asthma. Am. I Respir. Grit. Care Med. (1997) 154:1804–1811.
- HOLGATE ST, BODEY KS, JANEZIC A et al: Release of RANTES, MIP-la, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. .1 Respir. Grit. Care Med. (1997)156(5):1377–1383.
- RAJAKULASINGAM K, HAMID Q, O'BRIEN F et al: RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. Am. Respir Grit. Care Med. (1997) 155:696–703.
- ALAM R, YORK J, BOYARS M et al: Increased MCP-1, RANTES, and MIP-la in bronchoalveolar lavage fluid of allergic asthmatic patients. Am. I Respir. Grit. Care Med. (1996) 153(4 Part 0:1398–1404.
- TILLIE-LEBLOND I, HAMMAD H, DESURMONT S et al: CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment. Am. I Respir. Grit. Care Med. (2000) 162(2 Part 1):586–592.
- KRAMER ME OSTERTAG P, PFROGNER E, RASP G: Nasal IL-16 and MIP-la in late-phase allergic response. Allergy Asthma Proc. (2001) 22(3):127–132.
- BENSCH GW, NELSON HS, BORISH LC: Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. Ann. Allergy Asthma Immunol (2002) 88(5):457–462.
- KABURAGI Y, SHIMADA Y, NAGAOKA T et al: Enhanced production of CC-chemokines (RANTES, MCP-1, MIP-la, MIP- 113, and eotaxin) in patients with atopic dermatitis. Arch. Dermatol Res. (2001) 293(7):350–355.
- TEDLA N, WANG HW, McNEIL HP et al: Regulation of T lymphocyte trafficking into lymph nodes during an immune response by the chemokines macrophage inflammatory protein (MIP)- la and MIP-1 3. j Immunol (1998) 161(10):5663–5672.
- SABROE I, HARTNELL A, JOPLING LA et al.: Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. I Immunol (1999) 162(5):2946–2955.
- PHILLIPS R, STUBBS VE, HENSON MR, WILLIAMS TJ, PEASE JE, SABROE I: Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter. I Immunol (2003) 170(12):6190–6201.
- CAMPBELL EM, KUNKEL SL, STRIETER RM, LUKACS NW: Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. Immunol (1998) 161(12):7047–7053.
- GONZALO J-A, LLOYD CM, WEN D et al.: The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airways hyperresponsiveness. Exp. Med. (1998) 188(1):157–167.
- BLEASE K, MEHRAD B, STANDIFORD TJ et al: Airway remodeling is absent in CCR1 / mice during chronic fungal allergic airway disease. J. Immunol (2000) 165(3):1564–1572.
- LAFFARGUE M, CALVEZ R, FINAN P et al.: Phosphoinositide 3-kinase-y is an essential amplifier of mast cell function. Immunity (2002) 16(3):441–451.
- TODA M, DAWSON M, NAKAMURA T et al.: Impact of engagement of Fcc RI and CC chemokine receptor 1 on mast cell activation and motility../. Biol. Chem. (2004) 279(46):48443–48448.
- MIYAZAKI D, NAKAMURA T, TODA M et al: Macrophage inflammatory protein-la as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J. Clin. Invest. (2005) 115(2):434–442.
- PROUDFOOT AE, POWER CA, HOOGERWERF AJ et al: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. Biol. Chem. (1996) 271:2599–2603.
- PROUDFOOT AE, BUSER R, BORLAT F et al: Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors. J. Biol. Chem. (1999) 274(45):32478–32485.
- MATSUI M, WEAVER J, PROUDFOOT AE et al: Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. Neuroimmunol (2002) 128(1-2):16–22.
- GRONE HJ, WEBER C, WEBER KS et al.: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. (1999) 13(11):1371–1383.
- STOJANOVIC T, BEDKE J, GRONE HJ et al.: Met-RANTES inhibition of mucosal perfusion failure in acute intestinal transplant rejection - role of endothelial cell-leukocyte interaction. I Vasc. Res. (2002) 39(1):51–58.
- BEDKE J, STOJANOVIC T, GRONE HJ et al.: Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant. Proc. (2002) 34(3):1049.
- SONG E, ZOU H, YAO Y et al: Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. (2002) 61(2):676–685.
- YUN JJ, WHITING D, FISCHBEIN MP et al: Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. Circulation (2004) 109(7):932–937.
- VEILLARD NR, KWAK B, PELLI G et al: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Re.s (2004) 94(2):253–261.
- AJUEBOR MN, HOGABOAM CM, KUNKEL SL, PROUDFOOT AE, WALLACE JL: The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. Immunol (2001) 166(1):552–558.
- BONVILLE CA, LAU VK, DELEON JM et al.: Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J. Virol (2004) 78(15):7984–7989.
- BHATIA M, PROUDFOOT AE, WELLS TN et al.: Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis. Br. J. &mg. (2003) 90(6):698–704.
- ANDERS HJ, FRINK M, LINDE Y et al: CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. Immunol (2003) 170(11):5658–5666.
- PANZER U, SCHNEIDER A, WILKEN J et al.: The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int. (1999) 56(6):2107–2115.
- CHVATCHKO Y, PROUDFOOT AE, BUSER R et al.: Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. Immunol (2003) 171(105498–5506.
- ELSNER J, MACK M, BRUHL H et al: Differential activation of CC chemokine receptors by AOP-RANTES. J. Biol. Chem. (2000) 275(11):7787–7794.
- MACK M, LUCKOW B, NELSON PJ et al.: Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J. Exp. Med. (1998) 187(8):1215–1224.
- HESSELGESSER J, NG HP, LIANG M et al.: Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J. Biol. Chem. (1998) 273(25):15687–15692.
- ••The first description of a small-moleculeantagonist of CCR1.
- RICHELSON E: Preclinical pharmacology of neuroleptics: focus on new generation compounds. J. Clin. Psychiatry (1996) 57(Suppl 11):4–11.
- CUSACK B, NELSON A, RICHELSON E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) (1994) 114(4):559–565.
- LIANG M, MALLARI C, ROSSER M et al.: Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J. Biol. Chem. (2000) 275(25):19000–19008.
- ••Thorough characterisation of a small-molecule CCR1 antagonist.
- ANDERS HJ, VIELHAUER V, FRINK M et al: A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. (2002) 109(2):251–259.
- ••Thorough characterisation of a small-molecule CCR1 antagonist.
- GLADUE RP, TYLASKA LA, BRISSETTE WH et al.: CP-481715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J. Biol. Chem. (2003) 278(42):40473–40480.
- ••Thorough characterisation of a small-molecule CCR1 antagonist.
- HORUK R, SHUREY S, NG HP et al: CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunol Lett (2001) 76(3):193–201.
- HORUK R, CLAYBERGER C, KRENSKY AM et al.: A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. (2001) 276(6):4199–4204.
- NAYA A, SAGARA Y, OHWAKI K et al: Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem. (2001) 44(9):1429–1435.
- NAYA A, ISHIKAWA M, MATSUDA K et al: Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg. Med. Chem. (2003) 11(6):875–884.
- SABROE I, PECK MJ, VAN KEULEN B et al: A small molecule antagonist of the chemokine receptors CCR1 and CCR3: potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J. Biol. Chem. (2000) 275(34):25985–25992.
- DE MENDONCA FL, DA FONSECA PC, PHILLIPS RM et al: Site-directed mutagenesis of CC chemokine receptor 1 reveals the mechanism of action of UCB 35625, a small molecule chemokine receptor antagonist. J. Biol. Chem. (2005) 280(6):4808–4816.
- ••The first detailed description of how aproteotypic antagonist of CCR1 appears to function at the molecular level.
- BLANPAIN C, DORANZ BJ, BONDUE A et al.: The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. ./. Biol. Chem. (2003) 278(7):5179–5187.
- KATH JC, DIRICO AP, GLADUE RP et al: The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. Bioorg. Med. Chem. Lett. (2004) 14(9):2163–2167.
- KATH JC, BRISSETTE WH, BROWN MF et al.: Potent small molecule CCR1 antagonists. Bioorg. Med. Chem. Lett. (2004) 14(9):2169–2173.
- BROWN MF, AVERY M, BRISSETTE WH et al: Novel CCR1 antagonists with improved metabolic stability. Bioorg. Med. Chem. Lett. (2004) 14(9):2175–2179.
- SALCEDO RHO, OPPENHEIM JJ, WELNIAK LA, BLAZAR BR, MURPHY WJ: Drug Inhibition of graft-versus-host disease by a distamycin analogue that interferes with chemokine receptor function. Blood (1999)94(10 Suppl. 1):(Abstract 1738).
- ONUFFER J, McCARRICK MA, DUNNING L et al: Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1. J. Immunol (2003) 170(4):1910–1916.795 Expert Op/n. lnvestig. Drugs (2005) 14(7)
- SCHWARZ MK, WELLS TN: New therapeutics that modulate chemokine networks. Nat. Rev Drug Discov. (2002) 1(5):347–358.
- GARCIA-RAMALL E, MARQUES T, PRATS N et al: Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J. Immunol (2002) 169(10:6467–6473.
- OFFORD R: Peptides - The Wave of the Future (Part II) - Optimization of a superactive anti-HIV compound. Second International and 17th American Peptide Symposium, CA, USA, June 9 — 14 (2001).
- HORUK R: Society for Medicines Research - Chemokine Receptors and Drug Discovery, Horsham, UK, March 11(2004).
- LAROSA G: BPS Winter Meeting - Chemokine Antagonists - Future Selective Therapy for Infection, Inflammation, Asthma, Allergy Cancer and Transplantation, London, UK, December 17 (2001).
- RICE WG TJ, HUANG M, HOWARD OMZ, MICHEJDA CJ, BADER JP: New Types of anti-HIV agents identified by the NCI Drug Discovery Program. 11th International Conference on Antiviral Research, San Diego, CA, USA, April 5— 10 (1999).
- GLADUE RP: Discovery and characterization of a novel CCR1 antagonist, CP-481715. Inflammation Research Association Conference - Chemokines: Latest Advances and Clinical Outcomes, Boston, MA, USA, February 26 — 27 (2004).
- GODESSART N: CCR1 blockade in murine models of acute and chronic inflammation. Inflammation Research Association - 11th National Conference (Part VI), Bolton Landing, NY, USA. October 6 — 10 (2002).
- MADING P: 18F-Labelling of the CCR1 antagonist ZK-811460 for the diagnosis of Alzheimer's disease. Technical Exchange Meeting on Alzheimer Imaging, Berlin, Germany. October 30 (2003).
- BAUMAN J: CCR1 antagonists. Frontiers in Medicinal Chemistry - Annual Meeting Erlangen, Germany March 15 — 17 (2004).
Websites
- http://www.chemocentryx.comiproducti forest.html ChemoCentryx Forest Programme pipeline.
- http://smnorg.uldprevious_meetings/pdf/ march04.pdf Highlights from the Society for Medicines Research meeting March 11(2004).